Vitamin D and COPD
Phase 2
- Conditions
- Chronic obstructive pulmonary disease, unspecified.Chronic obstructive pulmonary disease, unspecified
- Registration Number
- IRCT138712271774N1
- Lead Sponsor
- Vice chancellor for research, Kerman University of Medical Sciences PhYsiology resaerch center of
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Including criteria: 1.Having COPD exacerbation 2.Age between 40 and 60 years 3.Moderate to severe disease. Exclusion criteria 1.Unwillingness to participate in the study, 2.Unable to perform spirometry, 3.History of any other respiratory disorder including asthma , bronchial carcinoma,lower respiratory tract infection 4. Recent (within 4 wk) hospitalization for COPD, 6.Any medical condition which needed more invasive respiratory support,6.Evidence of hypercalcemia, renal failure, hyperparathyroidism, malignancy, history of renal stone, cardiac arrhythmia, or patients who were using lithium.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 25(OH)2vit D3. Timepoint: first and 8th day. Method of measurement: Enzyme assay.;1,25(oh)2vitD3. Timepoint: first and 8th day. Method of measurement: Enzyme assay.;FEV1 and FVC. Timepoint: 8th day. Method of measurement: spirometry.
- Secondary Outcome Measures
Name Time Method C Reactive Protein,CRP. Timepoint: first and 8th day. Method of measurement: latex-enhanced immunoturbidimetric assay.;Serum Total Antioxidant. Timepoint: first and 8th day. Method of measurement: Calorimetry.